Clinical Trials Browser

Arsenic Trioxide × Clear all

NCT07504458 2026-04-16

QUATRO-APL

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Diseases, Leukemia, Neoplasms, Leukemia, Promyelocytic, Acute, Hematologic Neoplasms

NCT07348107 2026-01-16

ATARI-PDAC

Phase 1 Not yet recruiting

Neoplasm Metastasis

NCT07296445 2025-12-29

LATITUDE

Phase 3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Promyelocytic, Acute

NCT01409161 2025-12-17

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT06882031 2025-11-18

Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT07187505 2025-09-23

Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia

Phase NA Active not recruiting

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT06778187 2025-06-10

Oral-ATO for TP53-mutated Myeloid Malignancies

Phase 2 Recruiting

Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03503864 2025-05-21

Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma

Phase 2 Active not recruiting

80 enrolled 8 charts

Neuroblastoma

NCT06933394 2025-04-18

Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma

Phase 2 Recruiting

Neuroblastoma

NCT02688140 2025-02-26

TUD-APOLLO-064

Phase 3 Completed

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT06450145 2024-06-10

APL

Phase NA Recruiting

Neoplasms

NCT04793919 2024-04-15

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT04996030 2024-01-23

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

Phase 1 Suspended

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT06088030 2024-01-03

Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer

Phase 2 Recruiting

Neoplasms, Li-Fraumeni Syndrome

NCT00551460 2023-01-10

S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Phase 2 Completed

78 enrolled 8 charts

Other hematologic neoplasm

Leukemia, Leukemia, Promyelocytic, Acute

NCT03855371 2022-11-04

PANDA-T0

Phase 1 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05497310 2022-10-26

Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL

Phase 1/2 Unknown

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT00866918 2022-10-25

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Phase 3 Completed

106 enrolled 14 charts

MyeloidOther hematologic neoplasm

Childhood Acute Promyelocytic Leukemia With PML-RARA

NCT00482833 2022-10-12

APL0406

Phase 3 Completed

Other hematologic neoplasm

Leukemia, Leukemia, Promyelocytic, Acute

NCT03624270 2022-10-04

Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia

Phase 2 Unknown

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT01014546 2022-07-22

Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis

Phase 1 Terminated

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05297123 2022-03-28

Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid

Phase 1 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03751917 2022-01-04

APL0618

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT01404949 2021-11-30

Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy

Phase 2 Completed

17 enrolled 8 charts

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT02899169 2021-09-08

APL16

Phase 3 Unknown

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT02190695 2021-05-19

Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS

Phase 2 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04869475 2021-05-13

Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation

Phase 2 Unknown

Other solid neoplasm

Refractory Solid Tumors

NCT01470248 2021-02-17

Study of Arsenic Trioxide in Small Cell Lung Cancer

Phase 2 Completed

20 enrolled 8 charts

Lung Neoplasms, Carcinoma, Small Cell

NCT04695223 2021-01-06

Arsenic Trioxide for Structural p53 Mutations

Phase 2 Unknown

Neoplasms

NCT02699723 2020-10-22

Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer

Phase EARLY_PHASE1 Withdrawn

Carcinoma, Basal Cell

NCT00017433 2020-10-06

Arsenic Trioxide in Treating Patients With Multiple Myeloma

Phase 2 Terminated

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00017069 2020-10-05

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

Phase 2 Terminated

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00020969 2020-10-05

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Phase 2 Terminated

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00469209 2020-09-24

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

Phase 1/2 Completed

60 enrolled 7 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00234000 2020-07-31

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Phase 1 Terminated

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04489706 2020-07-28

Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation

Phase NA Unknown

Neoplasm Metastasis, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

NCT00274820 2020-07-27

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder

Phase 2 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00275067 2020-02-25

Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery

Phase 1/2 Unknown

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT01987297 2019-08-19

Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL

Phase 4 Unknown

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT00571116 2019-08-07

Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy

Phase 1 Terminated

Melanoma

NCT00413166 2019-05-07

All-trans Retinoic Acid, and Arsenic +/- Idarubicin

Phase 2 Completed

78 enrolled 10 charts

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT00006091 2018-11-14

Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment

Phase 2 Withdrawn

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01397734 2018-09-06

Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)

Phase 1 Terminated

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00004149 2018-08-17

Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy

Phase 2 Completed

Prostatic Neoplasms

NCT00104806 2018-08-10

Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes

Phase 2 Terminated

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT01791894 2018-06-08

ATO

Phase 1/2 Completed

5 enrolled 9 charts

Carcinoma, Basal Cell, Skin Neoplasms

NCT01835288 2018-05-21

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2 Withdrawn

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00118196 2018-05-11

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Phase 2 Terminated

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT03381781 2018-01-04

Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations

Phase 2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01428128 2017-12-13

Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector

Phase 2 Completed

50 enrolled 7 charts

Other hematologic neoplasm

Cancer Other Than Leukemia